T7 expression system-based Nissel 1917 engineering bacterium as well as preparation method and application of T7 expression system-based Nissel 1917 engineering bacterium

Through genetic engineering, E. coli Nissle 1917 was used to construct an engineered strain of the T7 expression system, which solved the endotoxin problem of E.coli in industrial production, and achieved efficient expression and safety improvement.

CN118931930AActive Publication Date: 2024-11-12BY HEALTH CO LTD

Patent Information

Application Number
CN202310516515.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-09
Publication Date
2024-11-12
Estimated Expiration
2043-05-09

AI Technical Summary

Technical Problem

The bacterial endotoxin produced by E. coli during culture causes host toxicity reactions. The existing removal methods are inefficient, poor specificity and toxic to the reagents used, which limits its wide application in industrial production.

Method used

E. coli Nissle 1917 was genetically engineered, the T7 RNA polymerase expression box was introduced and the cryptic plasmid was removed, and the engineered strain based on the T7 expression system was constructed. IPTG or lactose was used to induce the expression of exogenous proteins to avoid the production of endotoxins and simplify the product purification process.

Benefits of technology

It achieves efficient expression of exogenous proteins without endotoxins, improves the safety and simplification of the product, and is suitable for industrial production applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004219366980000111
    Figure BDA0004219366980000111
  • Figure BDA0004219366980000131
    Figure BDA0004219366980000131
  • Figure BDA0004219366980000141
    Figure BDA0004219366980000141
Patent Text Reader

Abstract

The invention provides a Nissible 1917 engineering bacterium based on a T7 expression system as well as a preparation method and application of the Nissible 1917 engineering bacterium. The Nissel 1917 engineering bacterium is suitable for inducible expression of foreign protein by IPTG or lactose, has high expression efficiency, does not contain endotoxin, simplifies purification of a target product in an industrial production process, improves use safety of the target product, and is suitable for application in industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of genetic engineering, and more specifically, to a Nissle 1917 engineering bacterium based on a T7 expression system, and a preparation method and application thereof. Background Art

[0002] Escherichia coli (E. coli) is a classic genetic engineering host for prokaryotic expression and is widely used in the field to express foreign genes. E. coli is a short rod-shaped Gram-negative bacterium and is currently the most widely used prokaryotic expression host in laboratories and industrial production, mainly including K-12 and B strains. The E. coli protein expression system has the following advantages: 1. The genetic background is clear, and a total of 4405 open reading frames were found through whole genome sequencing; 2. The molecular biology operation element system supporting E. coli is mature and complete; 3. It is easy to culture and control, the transformation operation is simple and efficient, the protein expression level is high, the cost is low, and the cycle is short.

[0003] However, E. coli, as a prokaryotic expression host, produces a type of bacterial endotoxin with a lipopolysaccharide (LPS) structure during the culture process, which can cause host toxicity. Bacterial endotoxins have a small molecular weight and are highly stable to heat and chemical reagents. Currently, ion exchange, adsorption, ultrafiltration and surfactants are mainly used to remove endotoxins from samples. However, the above methods still have problems such as low efficiency, poor specificity, toxic reagents used in the process that are difficult to remove, and high purification costs, which seriously restrict the widespread application of E. coli as a host bacteria in industrial production.

[0004] Therefore, finding a safer Escherichia coli as a host bacterium will greatly simplify the purification of the target product during industrial production and improve the safety of the target product. Summary of the invention

[0005] The purpose of the present invention is to provide an engineered bacterium of Escherichia coli Nissle 1917 based on a T7 expression system, which can be induced by IPTG or lactose to express exogenous proteins, has high expression efficiency, does not contain endotoxin, simplifies the purification of target products in the industrial production process, improves the safety of the target products, and is suitable for application in industrial production.

[0006] In a first aspect of the present invention, a method for transforming Escherichia coli Nissle 1917 is provided, comprising: (a) introducing an exogenous T7 RNA polymerase (T7 RNAP) expression cassette; and (b) removing a cryptic plasmid.

[0007] In a second aspect of the present invention, a Nissle 1917 engineered bacterium is provided, which is transformed from Escherichia coli Nissle 1917 and is a strain having the following characteristics: (a) containing an exogenous T7 RNA polymerase expression cassette; and (b) having its cryptic plasmid removed.

[0008] In one or more preferred embodiments, in (a), the T7 RNA polymerase expression cassette includes operably linked (5'-3'): an expression driver element, a modified ribosome binding site, and a T7 RNA polymerase encoding gene (preferably, also including a terminator).

[0009] In one or more preferred embodiments, the modified ribosome binding site includes a ribosome binding site of the 5'-aaagaggagaaa-3' sequence and a spacer sequence; the spacer sequence is 5'-ggccactactagag-3' located upstream (5' end) of the ribosome binding site, and 5'-tactag-3' located downstream (3' end) of the ribosome binding site.

[0010] In one or more preferred embodiments, the expression driving element includes: a lactose promoter and a lactose operon; more preferably, the lactose promoter is lacUV5; preferably, the lactose promoter has a sequence of 5'-tttacactttatgcttccggctcgtataatg-3', and the lactose operon has a sequence of 5'-ttgtgagcggataacaa-3'.

[0011] In one or more preferred embodiments, the T7 RNA polymerase expression cassette has the nucleotide sequence shown at positions 1-87 in SEQ ID NO:23.

[0012] In one or more preferred embodiments, the engineered bacteria further comprises: (c) down-regulating the endA gene.

[0013] In one or more preferred embodiments, the engineered bacteria further comprises: (d) down-regulating the ompT gene.

[0014] In one or more preferred embodiments, in (a), the T7 RNA polymerase expression cassette is introduced into the genome of Escherichia coli Nissle 1917.

[0015] In one or more preferred embodiments, the T7 RNA polymerase expression cassette is integrated into the attB site of the genome; preferably, the integration is performed by gene editing or homologous recombination.

[0016] In one or more embodiments, in (b)-(d), the downregulation or removal of the relevant gene or plasmid is performed by methods including (but not limited to) gene knockout / silencing and gene interference.

[0017] In one or more preferred embodiments, the down-regulation or removal is performed by gene knockout / silencing by gene editing or homologous recombination.

[0018] In one or more preferred embodiments, in (b), the cryptic plasmid includes: pMUT1, pMUT2.

[0019] In one or more embodiments, the cryptic plasmids pMUT1 and pMUT2 are knocked out by the CRISPR / Cas9 method; preferably, the specific sgRNA used is targeted to pMUT1 and pMUT2; more preferably, the sequence of the sgRNA targeting pMUT1 is shown in SEQ ID NO:1, and the sequence of the sgRNA targeting pMUT2 is shown in SEQ ID NO:2.

[0020] In one or more embodiments, endA and ompT are knocked out by CRISPR / Cas9 method. Preferably, the specific sgRNA used targets endA and ompT genes; more preferably, the sequence of the sgRNA targeting endA is shown in SEQ ID NO:31, and the sequence of the sgRNA targeting ompT is shown in SEQ ID NO:32.

[0021] In one or more embodiments, the cryptic plasmids pMUT1 and pMUT2 are knocked out by homologous recombination; preferably, it includes: using the Gibson homologous recombination method, using specific primer sequences, recombining the AmpR and sacB expression frames into the cryptic plasmid vector pMTU1 or pMTU2, transforming the strain, and screening and obtaining the recombinant strain; more preferably, the specific primer sequences are as shown in Table 1.

[0022] In one or more embodiments, endA and ompT are knocked out by homologous recombination.

[0023] In one or more preferred embodiments, the process comprises: preparing a homology arm sequence for knocking out endA or ompT, transforming the homology arm sequence and the vector fragment into a strain, performing PCR amplification using a specific primer sequence, and screening and obtaining a recombinant strain; preferably, the specific primer sequence is as shown in Table 5.

[0024] In the third aspect of the present invention, a recombinant expression system for foreign protein is provided, which comprises: (1) any of the Nissle 1917 engineered bacteria described above; and (2) an expression construct (expression vector), which comprises: a T7 promoter, and an insertion site for a foreign protein encoding gene (preferably, also comprising a terminator).

[0025] In one or more embodiments, the exogenous protein includes but is not limited to: functional protein and structural protein.

[0026] In one or more embodiments, the exogenous protein includes, but is not limited to, a regulatory protein, an enzyme (such as TEV enzyme), and a reporter protein (such as a fluorescent protein).

[0027] In one or more embodiments, the expression construct is a pET expression vector.

[0028] In a fourth aspect of the present invention, there is provided the use of any of the aforementioned Nissle 1917 engineered bacteria or the aforementioned recombinant expression system of foreign proteins for expressing foreign (heterologous) proteins.

[0029] In a fifth aspect of the present invention, a kit for expressing foreign proteins is provided, comprising: any one of the Nissle 1917 engineered bacteria described above; or, the recombinant expression system described above.

[0030] In one or more preferred embodiments, the kit further comprises an inducer, and the inducer comprises: lactose or IPTG.

[0031] In the fifth aspect of the present invention, a method for expressing exogenous protein using the recombinant expression system of exogenous protein is provided, comprising: (i) introducing the exogenous protein encoding gene into the exogenous protein encoding gene insertion site of the expression construct therein to obtain a recombinant expression construct; (ii) introducing the recombinant expression construct of (i) into the engineered bacteria to obtain recombinant engineered bacteria, culturing the recombinant engineered bacteria to express the exogenous protein.

[0032] In one or more preferred embodiments, in (ii), after culturing the recombinant engineered bacteria, it is induced with lactose or IPTG to express the foreign protein.

[0033] In the sixth aspect of the present invention, a modified ribosome binding site or a T7 RNA polymerase expression frame containing the site is provided, wherein the modified ribosome binding site comprises a ribosome binding site of the 5'-aaagaggagaaa-3' sequence and a spacer sequence; the spacer sequence is 5'-ggccactactagag-3' located upstream (5' end) of the ribosome binding site, and 5'-tactag-3' located downstream (3' end) of the ribosome binding site.

[0034] In one or more preferred embodiments, the T7 RNA polymerase expression cassette includes an operably linked (5'-3'): an expression driving element, a modified ribosome binding site and a T7 RNA polymerase encoding gene (preferably, also including a terminator); the expression driving element includes: a lactose promoter and a lactose operator; preferably, the lactose promoter is lacUV5; preferably, the lactose promoter has a sequence of 5'-tttacactttatgcttccggctcgtataatg-3', and the lactose operator has a sequence of 5'-ttgtgagcggataacaa-3'; more preferably, the T7 RNA polymerase expression cassette has the nucleotide sequence shown at positions 1-87 in SEQ ID NO:23.

[0035] In one or more preferred embodiments, the spacer sequence upregulates the expression of T7 RNA polymerase.

[0036] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 , EcNc strains; (a) and (b) are the PCR identification bands of the cloned pMTU1 and pMTU2 knockout plasmids, respectively; (c) is the identification band of the genomic DNA extracted from the original strain and EcNc strain, Lane1 and Lane2 correspond to the EcNc strain, and Lane3 and Lane4 correspond to the original strain.

[0038] Figure 2 :Schematic diagram of EcNc-T7 expression frame optimization.

[0039] Figure 3 :The expression levels of T7 RNA polymerase in strains obtained by different optimization methods were displayed by fluorescence intensity. Different letters between different groups indicate significant differences, P<0.05.

[0040] Figure 4 : Microscope photos of bacterial cells before and after optimization of the EcNc-T7 expression cassette under excitation by a white light source (a, c) and a 584 nm wavelength light source (b, d), respectively (the cryptic plasmid of the bacteria was knocked out by homologous recombination).

[0041] Figure 5:PCR amplification and sequencing identification map of EcNcΔattB (lacUV5-T7) strain; (a) is the PCR amplification result of the positive clone of the T7RNAP expression frame knock-in of the Escherichia coli EcNc strain; (b) is the assembly schematic diagram of the sequencing results of the T7RNAP expression frame at the knock-in site.

[0042] Figure 6 : Results of sequencing and identification of PCR products after endA (a) and ompT (b) gene knockout in EcNcΔattB (lacUV5-T7) strain.

[0043] Figure 7 : Red fluorescent protein expression of strains under different induction conditions: (a) no induction; (b) IPTG induction; (c) lactose induction; Group 1: Escherichia coli BL21 (DE3) strain; Group 2: Escherichia coli EcNc strain; Group 3: Escherichia coli EcNc-T7 strain; Group 4: Escherichia coli EcNc (lacUV5-T7) ΔendAΔompT strain.

[0044] Figure 8 :Identification of TEV protein expression in EcNcΔattB(lacUV5-T7)ΔendAΔompT strain under different induction conditions (ad). DETAILED DESCRIPTION

[0045] In order to solve the problems in the prior art that bacterial endotoxins are produced during fermentation production using conventional E. coli (BL21) as a host, and that the selection of prokaryotic engineered strains with high safety in the field and suitable for industrial large-scale production is single, the inventors have conducted in-depth research and provided an E. coli engineered bacterium based on Nissle1917, which can be induced to express by IPTG or lactose, has high expression efficiency, and does not contain endotoxins, simplifies the purification of the target product in the industrial production process, improves the safety of the target product, and is suitable for application in industrial production.

[0046] As used herein, "probiotics" refers to microbial cell preparations (eg, live microbial cells) that, when administered in an effective amount, provide a beneficial effect on the health or well-being of an individual. By definition, all probiotics have a demonstrated non-pathogenic character.

[0047] As used herein, "(genetically) engineered bacteria" refers to strains that have been genetically modified by genetic engineering methods to have capabilities and characteristics that the original strains do not have, thereby having certain functional uses. The present invention constructs a Nissle1917 engineered bacterium that has been genetically modified by genetic engineering methods to be able to express exogenous proteins.

[0048] As used herein, "Nissle1917 (EcN)", "Escherichia coli Nissle 1917" or "EcN" are used interchangeably. Escherichia coli Nissle 1917 (EcN) is a probiotic strain with a serotype of O6:K6:H1. This strain has high antagonistic activity against a variety of pathogens such as Salmonella, Yersinia enterocolitica, Shigella flexneri, etc. In addition to antibacterial activity, EcN also exhibits a variety of excellent properties, does not contain pathogenic factors such as enterotoxins, hemolytic toxins and cytotoxins, and poses no safety risks to the host. Currently, EcN probiotic preparations have been used to treat diarrhea, inflammatory bowel inflammation and constipation; and due to its safety performance to the host, it is also increasingly widely used in vaccines, tumor treatment and drug development. Unlike ordinary E. coli, EcN contains two cryptic plasmids pMUT1 (3.2kb) and pMUT2 (5.6kb) in its cytoplasm in addition to its own 5.4Mb genome. The pMUT1 plasmid carries a ColE1 replication system, while the pMUT2 plasmid carries a ColE2-like replication system, both of which can be stably inherited in the cell body. However, the application of the Nissle 1917 strain in the art is limited to being a probiotic, and no engineered host bacteria for efficient expression of heterologous genes have been successfully developed, and there are no molecular biological elements in its cells that can be used for the expression of exogenous proteins.

[0049] As used herein, "exogenous" refers to the relationship between two or more nucleic acid or protein sequences from different sources, or refers to the relationship between a protein / gene and a host cell. For example, although the host cell itself may also contain the corresponding gene or produce the corresponding protein, when the synthetic / recombinant gene / protein is introduced into the host cell by genetic engineering methods, it is "exogenous" with respect to the host cell. The "exogenous" includes "heterologous". "Heterologous" nucleic acids or proteins are usually not present in the host cell itself.

[0050] Using Escherichia coli Nissle 1917 as the starting strain, the genetic modification of the present invention includes: (a) introducing an exogenous T7 RNA polymerase (T7RNAP) expression frame; (b) removing the cryptic plasmid. In a more preferred embodiment, it also includes: (c) down-regulating the endA gene; and / or (d) down-regulating the ompT gene. The present invention enables the Nissle 1917 engineered bacteria to efficiently express exogenous proteins through systematic modification.

[0051] The endA gene expresses non-specific endonuclease I, which can unwind all DNA double strands and plays an important role in DNA replication and recombination. The endA gene can refer to NCBI accession number (949092). In the present invention, it was unexpectedly found that downregulation of the endA gene promoted the expression of foreign proteins.

[0052] The ompT gene expresses a specific outer membrane protein degrading enzyme, which specifically degrades the iron-containing enterobactin receptor protein bound to the cell membrane. The ompT gene can be found in NCBI accession number (945185). In the present invention, it is unexpectedly found that downregulation of the ompT gene promotes the expression of foreign proteins.

[0053] Downregulation of a gene includes "deletion / deficiency" or "inactivation" or "inhibition", meaning that the enzyme or protein encoded by the gene or coding region is not produced, or is produced in an inactive form in the host cell, or is produced in the host cell at a level lower than that found in the wild-type form of the host cell under the same or similar growth conditions. This can be achieved, for example, by one or more of the following methods: including homologous recombination, RNA interference-based technology, ZFN and TALEN, CRISPR / Cas system, etc.

[0054] In the present invention, various methods can be used to remove the cryptic plasmid, down-regulate the endA gene and / or down-regulate the ompT gene.

[0055] As a preferred method of the present invention, the CRISPR / Cas (such as Cas9) system can be used for targeted gene editing, thereby knocking out the secret plasmid, knocking out the endA gene and / or knocking out the ompT gene in the target area. Common knockout methods include: co-transferring sgRNA or a nucleic acid that can form the sgRNA, Cas mRNA or a nucleic acid that can form the Cas mRNA into the target area or target cell. After determining the target site, known methods can be used to introduce sgRNA and Cas into the cell.

[0056] In some specific embodiments, the cryptic plasmids pMUT1 and pMUT2 are removed by CRISPR / Cas9 technology, including: using specific sgRNAs targeting pMUT1 and pMUT2 genes; preferably, the sequence of the sgRNA targeting pMUT1 is shown in SEQ ID NO: 1, and the sequence of the sgRNA targeting pMUT2 is shown in SEQ ID NO: 2.

[0057] In some specific embodiments, the endA gene or the ompT gene is downregulated using CRISPR / Cas9 technology. Preferably, the sequence of the sgRNA targeting the endA gene is shown in SEQ ID NO:31, and the sequence of the sgRNA targeting the ompT gene is shown in SEQ ID NO:32.

[0058] As an optional method, homologous recombination can be used to specifically target the cryptic plasmid, knock out the endA gene and / or knock out the ompT gene, so that it has expression defects or lacks expression. Cre and loxp methods can also be used to selectively knock out related genes in the cell genome, reduce expression or inactivate them.

[0059] As an optional method, RNAi can be applied to the down-regulation or removal (such as interfering RNA molecules such as siRNA, shRNA, miRNA, etc.), and those skilled in the art will appreciate that such interfering RNA molecules can be prepared based on the information of the cryptic plasmid, endA gene and / or ompT gene provided in the present invention. The interfering RNA can be delivered to the cell by using an appropriate transfection reagent, or can also be delivered to the cell by using a variety of techniques known in the art.

[0060] "Increase", "introduction" or "knock-in" of a gene or coding region means that an enzyme or protein encoded by the gene or coding region is produced in a host cell, or is produced in a host cell at a higher level than that found in the wild-type form of the host cell under the same or similar growth conditions. When it is necessary to introduce into the genome, it can be achieved by one or more of the following methods, for example: Cre-loxp recombination system, CRISPR / Cas (such as Cas9) gene editing technology.

[0061] It is known to those skilled in the art that when selecting a site for introducing a T7 RNA polymerase-containing expression cassette (T7 RNAP) fragment into Nissle 1917, at least one of the following features is advantageous: (1) the one or more bacterial genes affected by the engineering of the site are not essential for the growth of Nissle 1917 and do not alter the biochemical and physiological activities of the host bacteria; (2) the site can be easily edited; (3) the T7 RNAP in the site can be transcribed. Common sites include, for example, bacterial phage attachment (attB) sites. In some specific embodiments, the T7 RNAP-containing expression cassette (T7 RNAP) fragment is introduced into Nissle 1917 using CRISPR / Cas9 technology.

[0062] As used herein, "T7 RNA polymerase" or "T7 RNAP" is an RNA polymerase with a molecular weight of about 99 kDa. It specifically catalyzes the RNA formation process in the 5'→3' direction. T7 RNA polymerase has a high promoter specificity and only transcribes the DNA or DNA replica located downstream of the T7 promoter in the T7 vector (expression vector).

[0063] In the present invention, by optimizing the design, a T7 RNA polymerase expression cassette is introduced into the genome of the Nissle 1917 strain, and the expression of the polymerase is enhanced by optimizing the design of the expression elements. The expression cassette includes an operably connected (5'-3'): expression driver element, a modified ribosome binding site (RBS) and a T7 RNA polymerase encoding gene. The modified ribosome binding site includes a 5'-aaagaggagaaa-3' ribosome binding site and a spacer sequence; the spacer sequence is 5'-ggccactactagag-3' located upstream (5' end) of the ribosome binding site, and 5'-tactag-3' located downstream (3' end) of the ribosome binding site. The expression driver elements include: a lactose promoter and a lactose operator. In a preferred embodiment, the arrangement of these elements is as follows Figure 2 The present invention may also include homologous sequences having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity thereto.

[0064] The present invention provides a recombinant expression system of foreign proteins, which includes the Nissle 1917 engineered bacteria obtained after transformation, and an expression construct (expression vector) carrying a T7 promoter, wherein there is a "T7 expression system".

[0065] The "T7 expression system" includes two key parts: T7 RNA polymerase and T7 promoter. T7 RNA polymerase acts on T7 promoter, giving the T7 system the ability to synthesize exogenous proteins. Represented by the pET vector system, the T7 promoter is completely and exclusively controlled by T7 RNA polymerase. When T7 RNA polymerase and T7 promoter are present in the cell at the same time, the transcription of T7 promoter can reach a very high level in a short time, and its transcription efficiency is much higher than the gene transcription level of the host cell itself. The T7 expression system is simple to construct, efficient, has high transcription efficiency, and strict regulation of target gene expression.

[0066] In some embodiments of the present invention, the T7 expression system is used to express exogenous (heterologous) proteins. As used herein, the term "exogenous (heterologous) protein" means that the protein is not native to the host cell because it is transplanted from a different organism into the host cell by a genetic engineering method and is not present in an unengineered host cell. The exogenous protein can be varied, including various functional proteins, structural proteins, etc. In the present invention, the coding gene of the exogenous protein is introduced into the expression construct carrying the T7 promoter.

[0067] The recombinant expression system of the exogenous protein operates as follows: when E. coli survives in an environment without lactose, the lac operon is in a repressed state; when lactose is present, lactose induces the lac operon, inducing the expression of the downstream gene, namely the coding gene of T7 RNA polymerase. T7 RNA polymerase recognizes T7 promoter and initiates the transcription / expression of its downstream gene. In the preferred embodiment of the present invention, the expression of T7 RNA polymerase is enhanced by modifying the ribosome binding site, and more T7 RNA polymerase is produced, thereby effectively promoting the expression efficiency of the exogenous protein in the recombinant expression system of the exogenous protein.

[0068] The expression construct (expression vector) carrying the T7 promoter may be a prokaryotic expression vector well known in the art, including, for example, a pET expression vector.

[0069] In some embodiments of the present invention, the exogenous protein is not a secretory protein. That is, the genetic engineering of the E. coli host does not need to make it have a "leaky" or destabilized outer membrane so that the exogenous protein is secreted outside the host cell.

[0070] In some exemplary embodiments, the exogenous protein can be a red fluorescent protein, and the exogenous protein gene includes a nucleic acid sequence as shown in SEQ ID NO:43, and a homologous sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity thereto.

[0071] In other exemplary embodiments, the exogenous protein may be a TEV protein. The exogenous protein gene includes a nucleic acid sequence as shown in SEQ ID NO: 44, and a homologous sequence having at least 80% (e.g., at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%) sequence identity therewith. The "TEV" is a cysteine ​​protease of tobacco etch virus (TEV) with a His tag (6X His tag) that can be recombinantly expressed in Escherichia coli, which can specifically recognize the heptapeptide sequence Glu-Asn-Leu-Tyr-Phe-Gln-Gly / Ser and perform enzymatic cleavage between Gln and Gly / Ser amino acid residues, and is often used to remove Glutathione S-transferase (GST), His or other tags of fusion proteins.

[0072] It is understood that exemplary foreign proteins are listed in the specific embodiments of the present invention, and the foreign protein expression system of the present invention can be applied to the expression of more foreign proteins, especially functional proteins with biopharmaceutical activity. That is, according to the Nissle 1917 engineered bacteria and experimental data methods provided by the present invention, those skilled in the art can apply the Nissle 1917 engineered bacteria of the present invention to the expression of one or more required foreign proteins as long as they can be expressed through the T7 expression system.

[0073] The present invention also provides a method for expressing foreign protein using the genetically engineered bacteria Nissle1917 (EcN) of the present invention, the method comprising: (1) connecting the gene of the foreign protein to an expression vector containing a T7 promoter to obtain a recombinant plasmid; (2) transforming the Nissle 1917 engineered bacteria using the recombinant plasmid described in (1); (3) inducing the expression of the foreign protein. In some specific embodiments, the induction comprises induction using lactose or IPTG.

[0074] Compared with the prior art, the present invention has the following advantages or positive effects:

[0075] (1) The present invention adds an optimized and modified ribosome binding site (including a spacer sequence) upstream of the promoter of T7 RNA polymerase, thereby improving the expression efficiency of T7 RNA polymerase and laying a foundation for the high-efficiency expression of foreign proteins;

[0076] (2) The present invention significantly improves the expression level of exogenous proteins by knocking out the endA and ompT genes in the Nissle 1917 engineered bacteria;

[0077] (3) The present invention constructs an exogenous protein expression system based on Escherichia coli Nissle 1917, which can be induced by IPTG or lactose and has a very high expression efficiency.

[0078] (4) As a probiotic, Escherichia coli Nissle 1917 has the advantages of antibacterial activity, lacking pathogenic factors such as enterotoxins, hemolytic toxins and cytotoxins, and having no safety risks.

[0079] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.

[0080] Example 1: Obtaining EcNc by knocking out the cryptic plasmids pMTU1 and pMTU2 of probiotic Escherichia coli Nissle1917 based on CRISPR / Cas9 gene editing technology

[0081] In the present invention, CRISPR / Cas9 gene editing technology is used in the original strain Escherichia coli Nissle1917 (E. coli Nissle1917), sgRNAs of cryptic plasmids pMTU1 and pMTU2 are designed respectively to knock them out, and an Escherichia coli strain with cryptic plasmids removed is constructed and named EcNc.

[0082] in:

[0083] sgRNA-pMTU1: agttaccggataaggcgcagcgg (SEQ ID NO: 1);

[0084] sgRNA-pMTU2: gtttggcgcagaacctcggacgg (SEQ ID NO: 2).

[0085] The method of transforming the CRISPR / Cas9 knockout system into the target strain E. coli Nissle1917 is as follows:

[0086] (i) preparing an electroporation competent E. coli Nissle1917 strain;

[0087] (ii) using a homologous recombination kit (Pro Ligation-Free Cloning Kit, abm, catalog number E086) to connect the Cas9 fragment with the NcoI enzyme / XhoI enzyme double enzyme digested fragment of the pKD46 plasmid to construct the pKD-Cas9 plasmid;

[0088] (iii) The pKD-Cas9 plasmid was transformed into E. coli Nissle1917 cells, and the bacterial solution was spread on Kan-resistant plates and cultured at 30°C;

[0089] (iv) The next day, a single clone was picked for PCR verification, and the positive clone was used to prepare electrocompetent cells, which were named EcN-Cas9;

[0090] (v) pUC-sgRNA-pMTU1 and pUC-sgRNA-pMTU2 were transferred into EcN-Cas9 cells, and the bacterial solution was spread on Kan+Spec resistance plates and cultured at 30°C;

[0091] (vi) The next day, a single clone was picked and expanded for culture, the target gene was amplified using PCR primers (SEQ ID NOs: 3 to 6), and the target gene was identified by agarose gel electrophoresis;

[0092] pMTU1-F: ccctttttctgatttcctggtc (SEQ ID NO: 3);

[0093] pMTU1-R: ttctgggtctttgtcttttgctc (SEQ ID NO: 4);

[0094] pMTU2-F: gcaacccaacattgtcattattt (SEQ ID NO: 5);

[0095] pMTU2-R: cttagcacccgctttaccttta (SEQ ID NO: 6);

[0096] (vii) picking up clones without bands and re-streaking for screening;

[0097] (viii) The next day, a single clone was picked and expanded for culture, the target gene was amplified using primers, and then identified by agarose gel electrophoresis;

[0098] (ix) picking up clones without bands and inoculating them into fresh culture medium to extract genomic DNA;

[0099] (x) Genomic DNA agarose gel electrophoresis confirmed the complete removal of pMTU1;

[0100] (xi) selecting the strain with pMTU1 removed, and performing knockout of the pMTU2 plasmid based on the same steps as above;

[0101] (xii) The strain in which both pMTU1 and pMTU2 were removed was identified as a gene-edited strain by dual identification by PCR and genomic DNA agarose gel electrophoresis and was named EcNc.

[0102] PCR and genomic DNA electrophoresis patterns of EcNc strains are shown in Figure 1 As shown, (a) and (b) are the PCR identification results of clones with pMTU1 and pMTU2 knockout plasmids, respectively, showing that both primer pairs did not amplify visible bands; (c) is the genomic DNA extracted from the original strain and the EcN strain, and the results show that the EcNc strain has no visible pMTU1 and pMTU2 bands, indicating that the cryptic plasmids pMTU1 and pMTU2 of E. coli Nissle1917 have been successfully and completely removed.

[0103] Example 2: Obtaining EcNc by knocking out the cryptic plasmids pMTU1 and pMTU2 of probiotic Escherichia coli Nissle1917 based on homologous recombination

[0104] In this embodiment, homologous recombination was used to knock out the Nissle1917 cryptic plasmids pMTU1 and pMTU2, and the steps included (primer sequences are shown in Table 1):

[0105] (1) The cryptic plasmids pMTU1 and pMTU2 of Escherichia coli Nissle 1917 strain (EcN) were extracted by alkaline lysis method, and pMTU1 and pMTU2 were separated by agarose gel electrophoresis and recovered separately.

[0106] (2) Plasmids pMTU1 and pMTU2 were digested with SphI endonuclease at 37°C, and subjected to agarose gel electrophoresis and gel extraction.

[0107] (3) Using pUC57-Amp as a template, the AmpR expression cassette (SEQ ID NO: 15) was amplified using the Amp-pMTU2-F / Amp-pMTU1 / 2-R or Amp-pMTU1-F / Amp-pMTU1 / 2-R primer pair; using pRE112 as a template, the SacB-pMTU1 / 2-F / SacB-pMTU1-R or SacB-pMTU1 / 2-F / SacB-pMTU2-R primer pair was amplified using the sucrose sensitive gene (SacB) expression cassette (SEQ ID NO: 16); the PCR products were subjected to agarose gel electrophoresis and the gel was excised and recovered.

[0108] (4) The AmpR and sacB expression cassettes were recombined into the cryptic plasmid vectors pMTU1 and pMTU2 by the Gibson homologous recombination method, named pMTU1-Amp and pMTU2-Amp, respectively, and transformed into DH5α competent cells and plated on Amp-resistant LB plates and cultured at 37°C overnight.

[0109] (5) The next day, a single colony was picked and inoculated into Amp-resistant LB liquid culture medium, and positive clones were identified by PCR using the Amp-SacB-JJF / Amp-SacB-JJR primer pair.

[0110] (6) Extract the plasmid of the positive clone and sequence to verify the accuracy of the recombinant sequence.

[0111] (7) Extract the correctly cloned plasmid, electroporate it into the competent EcN strain, and after recovery incubation, spread it onto an Amp-resistant LB plate and culture it at 37°C overnight.

[0112] (8) Pick a single colony and inoculate it into Amp-resistant LB liquid medium. Use the Amp-SacB-JJF / Amp-SacB-JJR primer pair to identify the positive clone by PCR and extract the plasmid for sequencing verification. The strain carrying the recombinant plasmid is named EcN-pMTU1-Amp or EcN-pMTU2-Amp.

[0113] (9) EcN-pMTU1-Amp or EcN-pMTU2-Amp was subcultured three times on an Amp-resistant LB plate. Single colonies were picked again for PCR screening to identify strains carrying the recombinant plasmid without the original cryptic plasmid pMTU1 or pMTU1, and the plasmid was extracted for electrophoresis verification.

[0114] (10) The positive clones were inoculated into antibiotic-free LB liquid medium containing 10% sucrose for expansion and culture, and then subcultured three times on 10% sucrose antibiotic-free LB plates.

[0115] (11) Use the primer pairs pMTU1-JJF / pMTU1-JJR or pMTU2-JJF / pMTU2-JJR to screen clones with pMTU1-Amp or pMTU2-Amp plasmid removed by PCR. Culture the positive clones on both antibiotic-free and Amp-resistant LB plates. Select the Amp-resistant and sensitive clones for expansion and extraction of plasmids for electrophoresis to identify the plasmid removal status.

[0116] (12) Repeat steps 7 to 11 to remove another cryptic plasmid of EcN, extract the plasmid and perform electrophoresis to identify the plasmid removal status, and finally obtain Escherichia coli with two cryptic plasmids removed and antibiotic-sensitive, named EcNc.

[0117] Table 1 Primers used in the process of cryptic plasmid removal

[0118]

[0119] The cells obtained in this example and in Example 1 were analyzed and compared, and the results showed that knocking out the cryptic plasmid by CRISPR and knocking out the cryptic plasmid by homologous recombination left no traces in the cells. Therefore, the bacteria obtained by the two methods were consistent.

[0120] Example 3, Optimization of T7-RNAP expression cassette

[0121] The T7-RNAP expression cassette on the genome of conventional Escherichia coli BL21 (DE3) contains the lac UV5 promoter, lac operator (LacO), lacZ gene and T7 RNA polymerase gene. However, Nissle 1917 does not contain the T7RNAP expression cassette and cannot express foreign genes. In order to enable Nissle 1917 to express T7 RNA polymerase, the T7RNAP expression cassette needs to be inserted into the genome of Nissle1917 bacteria. Furthermore, in order to improve the expression of T7 RNA polymerase, the expression cassette was simplified and the expression was optimized: 1) The optimized expression regulation system is still the lactose operation system, and its promoter and operator sequences are consistent with those of Escherichia coli, but the lacZ gene is deleted; 2) An RBS sequence and a new spacer sequence are added upstream of the start codon of the T7 RNA polymerase gene to improve the transcription and translation of the T7 RNA polymerase gene; 3) The optimized expression cassette is inserted into the PET vector and transformed into EcNc to evaluate the expression efficiency of the optimized system.

[0122] In step 2), the inventors designed and compared the effects of sequence optimization expression formed by combinations of different RBS and spacer sequences. These combinations are shown in Table 2. The different optimized sequence structures and compositions are shown in Table 2. Figure 2 The primer sequences are shown in Table 3.

[0123] Table 2

[0124] Serial number Strain number Sequence combination 1 BL21(DE3) lacUV5+lacO+spacer1+RBS1+LacZ+T7RNAP 2 EcNc-T7-1 lacUV5+lacO+spacer2+RBS2+T7RNAP 3 EcNc-T7-2 lacUV5+lacO+spacer1+RBS1+T7RNAP 4 EcNc-T7-3 lacUV5+lacO+spacer2+RBS1+T7RNAP 5 EcNc-T7-4 lacUV5+lacO+spacer1+RBS2+T7RNAP

[0125] RBS1: AGGAAA; RBS2: AAAGAGGAGAAA;

[0126] spacer1: TTTCACAC (upstream of RBS) + CAGCT (downstream of RBS);

[0127] spacer2: GGCCACTACTAGAG (upstream of RBS) + TACTAG (downstream of RBS).

[0128] The specific steps are as follows:

[0129] (1) Design primer pair T7-RNA-F / T7-RNA-R based on the genome sequence of strain BL21 (DE3) on NCBI, amplify the T7-RNA polymerase gene and sequence it for verification;

[0130] (2) Gene synthesis of regulatory elements upstream of the T7-RNA polymerase gene, such as the lac UV5 promoter, lac operator, and RBS. The complete fragment can be amplified using Promoter-F / Promoter-R and named PlacUV5-lacO-RBS;

[0131] (3) Using Promoter-F / T7-RNAP-R, the regulatory element and the T7-RNA polymerase gene in step (1) were assembled into a linear fragment (named T7-RNAP) by PCR reaction and sequenced for verification;

[0132] (4) While steps (1) to (3) are being performed, the fluorescent vector is constructed simultaneously. The pET-28a vector is digested with NcoI / XhoI and the mRFP fluorescent protein encoding gene is inserted into the pET-28a vector, which is named pET-mRFP;

[0133] (5) After pET-mRFP sequencing was correct, pET-mRFP was digested with SphI and the linearized fragment was recovered. The T7-RNAP expression cassette was amplified using the primer pair T7-RNAP-FN / T7-RNAP-RN and inserted into the pET-mRFP vector by homologous recombination, named pET-mRFP-T7RNAP;

[0134] (6) pET-mRFP-T7RNAP was transformed into the Nissle 1917 strain (EcNc) with the cryptic plasmid removed, spread on a resistance plate, and cultured at 37°C overnight;

[0135] (7) Pick a single clone from step (6), inoculate it into fresh LB medium, and culture it overnight at 37°C and 220 rpm. This bacterial solution is the seed solution;

[0136] (8) The seed solution obtained in step (7) was inoculated into fresh LB medium at a ratio of 1:100, and cultured at 37°C and 220 rpm until the OD600 of the bacterial solution reached about 0.6;

[0137] (9) Add IPTG (final concentration 0.5 mM) to the bacterial solution and incubate at 37°C and 220 rpm for 3 h;

[0138] (10) Collect bacterial culture samples and observe the expression of pET-mRFP-T7RNAP in the EcNc strain using a fluorescence microscope.

[0139] Table 3. Sequences used in the optimization process of T7-RNAP expression cassette

[0140]

[0141] like Figure 2As shown, after optimization of the present invention, the promoter sequence is "tttacactttatgcttccggctcgtataatg", the operator sequence is "ttgtgagcggataacaa", the RBS sequence is "AAAGAGGAGAAA", the spacer sequence is "GGCCACTACTAGAG" (RBS upstream spacer sequence) and "TACTAG" (RBS downstream spacer sequence), and the expression frame they constitute is abbreviated as "lacUV5-T7".

[0142] In SEQ ID NO: 23, "ATGAACACGATTAACATCGCTAAGAAC" is the upstream partial sequence of the gene encoding T7 RNA polymerase (Gene ID: 1261050), and ATG is the start codon.

[0143] like Figure 3 and Figure 4 As shown, the optimized T7RNAP of the present invention can be efficiently expressed in EcNc, while the original T7-RNAP expression frame sequence of BL21 (DE3) has low expression efficiency in EcNc. For different RBS and spacer sequences, there are significant differences in the effects after their combination.

[0144] Example 4. Construction of probiotic Escherichia coli EcNcΔattB (lacUV5-T7) strain

[0145] The EcNcΔattB (lacUV5-T7) strain prepared by the present invention is referred to as the EcNc-T7 strain for short. The insertion site of the expression frame "lacUV5-T7" is consistent with that of Escherichia coli BL21 (DE3), both of which are attB sites on the genome.

[0146] 4.1 Construction of EcNcΔattB (lacUV5-T7) strain using CRISPR / Cas9 gene editing technology

[0147] The present inventors designed sgRNA for the attB site of the EcN genome (the nucleotide sequence of the sgRNA for the attB site is shown in SEQ ID NO: 24).

[0148] sgRNA-attB: CTAACTTGAGCGAAACGGGAAGG (SEQ ID NO: 24).

[0149] The same method as in Example 1 was used to construct EcNc-Cas9, and then the pUC-sgRNA-attB plasmid and the donor fragment (the donor fragment contained the T7 RNAP fragment and homology arms of about 300 bp upstream and downstream of the attB site) were co-transfected into the EcNc-Cas9 cells, and the T7 RNAP fragment was integrated into the attB site of the EcNc strain using the CRISPR / Cas9 system (steps vi to ix in Example 1 were skipped during the operation).

[0150] The positive clones obtained by screening were used as templates to perform PCR amplification through the upstream and downstream sequences of the CRISPR / Cas9 knock-in site, and the correct bands were recovered by agarose gel and sequenced for verification. The PCR primers used are shown in SEQ ID NO: 25-26, and the results are shown in Figure 5 As shown, from the assembly results of the sequencing results, the knock-in fragment sequence is consistent with the T7RNAP fragment, indicating that the T7RNAP expression frame was successfully knocked into EcNc, and it was named EcNcΔattB (lacUV5-T7), namely EcNc-T7.

[0151] EcNc-F: cgtggtatgcgttacaccttgagt (SEQ ID NO: 25);

[0152] EcNc-R: ctggtggcactgggtagttgttaat (SEQ ID NO: 26).

[0153] 4.2 Construction of EcNcΔattB (lacUV5-T7) strain using homologous recombination technology

[0154] Homologous recombination can also insert T7 RNA into EcNc. The specific steps are as follows (primer sequences are shown in Table 4):

[0155] (1) Primers T7-RNAP-F1 / T7-RNAP-R1 were used to amplify the T7-RNAP expression cassette using pET-mRFP-T7RNAP as a template. The PCR product was subjected to agarose gel electrophoresis and recovered.

[0156] (2) Plasmid pKD3 was digested with SphI, and T7-RNAP was recombined into plasmid pKD3 by Gibson homologous recombination. The final construct was named pKD3-T7RNAP.

[0157] (3) pKD3-T7RNAP was positively identified by PCR screening and verified by gene sequencing.

[0158] (4) Use the T7-RNAP-F2 / -R2 primer pair with pKD3-T7RNAP as a template to amplify the target fragment + FRT + CmR expression element + FRT sequence, and add about 50 bp upstream and downstream of the knockout site at both ends of the fragment. The final fragment is named T7-CmR fragment.

[0159] (5) The recombination process is the same as the homologous recombination knockout process of the cryptic plasmids pMTU1 and pMTU2 in Example 2.

[0160] (6) The recombinant fragment was amplified by PCR using the EcN-F / EcN-R primer pair, and sequencing verification results showed that the T7RNAP expression frame was successfully knocked in.

[0161] Table 4. Primer sequences used in the construction of EcNcΔattB (lacUV5-T7) strain using homologous recombination technology

[0162]

[0163] Example 5: Establishment of EcNcΔattB(lacUV5-T7)ΔendAΔompT using CRISPR / Cas9 system

[0164] In this example, the endA and ompT genes in the probiotic Escherichia coli EcNcΔattB (lacUV5-T7) strain were knocked out based on CRISPR / Cas9 gene editing technology to prepare EcNcΔattB (lacUV5-T7)ΔendAΔompT.

[0165] The sgRNAs of the genes endA (the sgRNA nucleotide sequence of endA is shown in SEQ ID NO: 31) and ompT (the sgRNA nucleotide sequence of ompT is shown in SEQ ID NO: 32) were designed respectively, and the CRISPR / Cas9 knockout system was transformed into the target strain EcNcΔattB (lacUV5-T7) by the same method as in Example 1, i.e., EcNc-T7 to knock out the target gene.

[0166] sgRNA-endA: TTTTTCTCAAGCGAAAGCCGCGG (SEQ ID NO: 31);

[0167] sgRNA-ompT: TACTCCTGACAACATAAATGCGG (SEQ ID NO: 32);

[0168] Using the positive clone as a template, PCR primers (as shown in SEQ ID NOs: 33 to 36) were used to amplify the CRISPR / Cas9 gene knockout site endA and the upstream and downstream sequences of the ompT gene, and the correct bands were recovered using agarose gel and sequenced for verification.

[0169] The results are as follows Figure 6 (a) and Figure 6 As shown in (b), the sequence of the knockout fragment was consistent with the fragments of the endA and ompT genes, indicating that the endA and ompT genes were successfully knocked out in the EcNcΔattB (lacUV5-T7) strain, and it was named EcNcΔattB (lacUV5-T7)ΔendAΔompT.

[0170] ompT-F:cattcgggaaggagccgatatcat(SEQ ID NO:33);

[0171] ompT-R: ctaatatgcatctaaaggcatggcact (SEQ ID NO: 34);

[0172] endA-F: ​​tacgccgtcataatcgcgtagt (SEQ ID NO: 35);

[0173] endA-R: tgaaatcgaccttcatggcgcat (SEQ ID NO: 36).

[0174] Example 6: Establishment of EcNcΔattB(lacUV5-T7)ΔendAΔompT by homologous recombination

[0175] In this example, the endA and ompT genes in the probiotic Escherichia coli EcNcΔattB (lacUV5-T7) strain were knocked out based on homologous recombination technology to obtain EcNcΔattB (lacUV5-T7)ΔendAΔompT, which was named TCBJ117.

[0176] 6.1 Knockout of ompT gene

[0177] (1) The universal primers P1 / P2 were used to amplify the FRT+CmR expression element+FRT sequence (CmR fragment) using PKD3 as a template. The PCR product was subjected to agarose gel electrophoresis and recovered by gel excision.

[0178] (2) Using the ompT-P1 / ompT-P2 primers, PCR was performed to add homology arms of about 50 bp on both sides of the ompT gene knockout site (ompT-CmR fragment) at both ends of the CmR fragment. The PCR product was subjected to agarose gel electrophoresis and recovered by gel excision.

[0179] (3) Prepare the competent EcNc strain and transform the pKD46 plasmid into the target strain, named EcNc-pKD46.

[0180] (4) Activate the EcNc-pKD46 strain and inoculate a single clone into Amp-resistant LB medium for overnight culture as seed solution; the next day, re-inoculate the seed solution, add 0.2% arabinose and expand the culture at 30°C until the OD600 reaches 0.4-0.5, and collect the bacteria to prepare the competent state.

[0181] (5) The ompT-CmR fragment was transformed into the competent cell of EcNc-pKD46 in step (4), transferred to LB liquid culture medium containing Amp and Cm antibiotics, and cultured at 30°C overnight.

[0182] (6) Take an appropriate volume and spread it on a Cm-resistant LB plate and culture it at 37°C overnight.

[0183] (7) Use EcNc-ompT-F / EcNc-ompT-R primers to amplify the fragment of about 1000 bp upstream and downstream of the knockout site by PCR, and confirm the gene knockout strain by gene sequencing.

[0184] (8) Pick the positive clones in step (7) and prepare competent cells of the strain.

[0185] (9) The pCP20 plasmid was transformed into the knockout strain and inoculated into LB culture medium with Amp and Cm resistance and cultured at 30°C overnight.

[0186] (10) The bacterial culture was transferred to fresh LB medium and cultured at 42°C for 1 h. Appropriate bacterial culture was spread on antibiotic-free, Amp, and Cm resistance plates to screen for antibiotic-sensitive strains, which were the knockout strain EcNcΔompT without resistance.

[0187] (11) PCR amplified the recombinant fragments and sequenced to verify the knockout status. It was verified that this method successfully knocked out the relevant genes.

[0188] 6.2 Knockout of endA gene

[0189] The procedure is similar to that of knocking out the ompT gene.

[0190] Table 5. Primer sequences used in the gene knockout process in Example 6

[0191]

[0192] Example 7: Functional verification of the probiotic Escherichia coli EcNcΔattB(lacUV5-T7)ΔendAΔompT strain

[0193] In order to verify the effect of the transformed strain EcNcΔattB (lacUV5-T7) ΔendAΔompT in Example 6 as a host bacteria for the efficient expression of heterologous proteins by a vector containing a T7 promoter, red fluorescent protein (mRFP) and tobacco etch virus TEV protein were used as examples for verification. The genes of red fluorescent protein (mRFP, gene sequence as shown in SEQ ID NO: 43) and tobacco etch virus TEV protein (gene sequence as shown in SEQ ID NO: 44) were cloned into the pET28a vector to obtain pET-mRFP and pET-TEV prokaryotic expression vectors, and then transformed into the EcNcΔattB (lacUV5-T7) ΔendAΔompT strain, and BL21 (DE3) transformed with the same plasmid was used as a control, and compared with the EcNc-T7 strain. IPTG or lactose was added for induction for 1 to 4 hours, and the expression level of TEV was detected by SDS-PAGE electrophoresis.

[0194] 1. Construction of pET-mRFP or pET-TEV prokaryotic expression vector

[0195] (1) PCR amplified the mRFP and TEV gene fragments respectively, and the primers were as follows:

[0196] mRFP-F (SEQ ID NO: 45):

[0197] GTTTAACTTTAAGAAGGAGATATACCATGGCTTCCTCCGAAGACGTTATC;

[0198] mRFP-R (SEQ ID NO: 46):

[0199] GTGGTGGTGGTGGTGCTCGAGCTATTAAGCACCGGTGGAGTGACGACC;

[0200] TEV-F (SEQ ID NO: 47):

[0201] gtttaactttaagaaggagatataccatgggccaccatcatcatcatcatag;

[0202] TEV-R (SEQ ID NO: 48):

[0203] ggtggtggtggtggtgctcgagctattagttcatcagctgggtagcttc;

[0204] (2) pET28a plasmid was double digested with NcoⅠ and XhoⅠ;

[0205] (3) gel electrophoresis and gel cutting to recover the mRFP, TEV amplified fragments and pET28a double enzyme digested fragments;

[0206] (4) Using a homologous recombination kit (Pro Ligation-Free Cloning Kit), the mRFP and TEV fragments were connected to the pET28a double-enzyme fragment respectively; the ligation products were transformed into DH5α competent cells, and the transformation solution was coated on an LB plate containing Kan antibiotics and incubated at 37°C overnight;

[0207] (5) Single colonies were selected for PCR identification and sequencing verification to construct the vector pET-mRFP or pET-TEV.

[0208] 2. Vector transformation

[0209] The pET-mRFP or pET-TEV plasmid was transformed into BL21 (DE3), EcNc-T7 and EcNcΔattB (lacUV5-T7) ΔendA ΔompT competent cells, respectively, spread on Kan-resistant plates and cultured inverted at 37°C overnight. The next day, single clones were picked from the plates and inoculated into 5 mL test tubes containing LB liquid culture medium containing Kan antibiotics, and cultured at 37°C 220 rpm overnight to obtain recombinant expression strains.

[0210] 3. Inducible expression

[0211] (1) The overnight culture containing the pET-mRFP plasmid (recombinant expression strain) was inoculated into a test tube containing 4 mL of LB culture medium (containing Kan antibiotic) at a ratio of 1:100 and cultured at 37°C and 220 rpm; after culturing for about 2 to 3 hours until the OD600 value reached 0.6 to 0.8, IPTG with a final concentration of 0.5 mM or 1% lactose was added and cultured for another 2 to 3 hours at 25°C and 220 rpm.

[0212] (2) Overnight culture containing pET-TEV plasmid (recombinant expression strain) The overnight culture was inoculated into 50 mL of LB culture medium (containing Kan antibiotic) in a 250 mL Erlenmeyer flask at a ratio of 1:100 and cultured at 37°C and 220 rpm; cultured for about 2 to 3 hours until the OD600 value reached 0.6 to 0.8, then IPTG or 1% lactose was added at a final concentration of 0.5 mM and cultured for another 3 to 4 hours at 25°C and 220 rpm.

[0213] 4. Product testing

[0214] The pET-mRFP plasmid was induced to express and the results were as follows: Figure 7As shown, EcNcΔattB(lacUV5-T7)ΔendAΔompT can express red fluorescent protein under the induction of ITPG or lactose like the BL21(DE3) strain; the EcNc-T7 strain can also express red fluorescent protein, but the expression level is lower than that of EcNcΔattB(lacUV5-T7)ΔendAΔompT; and EcNc cannot be induced to express red fluorescent protein.

[0215] The induced expression of pET-TEV plasmid was quantitatively analyzed, the bacteria were collected, and then the cells were broken and the protein was extracted for relative quantitative determination by SDS-PAGE electrophoresis.

[0216] The results are as follows Figure 8 As shown in the figure, (1) the EcNcΔattB(lacUV5-T7)ΔendAΔompT strain can achieve high-level protein expression for pET-TEV plasmid under IPTG or lactose induction. The constructed system can use safe and cheap lactose instead of IPTG to induce recombinant bacteria, which not only reduces costs but also enables downstream products to meet the safety standards of medicines and foods. (2) The expression level of pET-TEV plasmid induced by the EcNcΔattB(lacUV5-T7)ΔendAΔompT strain reaches the expression level of the BL21(DE3) strain. This shows that under the same conditions, the EcNcΔattB(lacUV5-T7)ΔendAΔompT strain can achieve high-level expression of foreign proteins. In fact, the EcNcΔattB(lacUV5-T7)ΔendAΔompT strain showed significantly better expression than BL21(DE3) when induced by lactose. (3) The EcNcΔattB(lacUV5-T7)ΔendAΔompT strain had a significantly higher expression level induced by the pET-TEV plasmid than that of EcNc-T7 (p<0.05), indicating that the knockout of the endA and ompT genes can significantly enhance the expression of heterologous genes.

[0217] Furthermore, the same method was used to verify the expression function of the EcNcΔattB(lacUV5-T7)ΔendAΔompT strain prepared by the method in Example 5. The results showed that the strain prepared by this method can also efficiently express exogenous proteins and can be induced by IPTG and lactose at the same time, and there is no significant difference in expression ability with the BL21(DE3) strain.

[0218] In summary, EcNcΔattB(lacUV5-T7)ΔendAΔompT optimized and constructed by the method of the present invention is an excellent strain that can be combined with T7 promoter expression vectors such as pET series vectors to form a new safe and efficient probiotic Escherichia coli expression system for inducing stable expression of exogenous proteins.

[0219] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.

[0220] Sequence information summary

[0221] SEQ ID NO: 1

[0222] AGTTACCGGATAAGGCGCAGCGG

[0223] SEQ ID NO: 2

[0224] GTTTGGCGCAGAACCTCGGACGG

[0225] SEQ ID NO: 3

[0226] CCCTTTTTCTGATTTCCTGGTC

[0227] SEQ ID NO: 4

[0228] TTCTGGGTCTTTGTCTTTTGCTC

[0229] SEQ ID NO: 5

[0230] GCAACCCAACATTGTCATTATTT

[0231] SEQ ID NO: 6

[0232] CTTAGCACCCGCTTTACCTTTA

[0233] SEQ ID NO:7

[0234] CGACAGGGTTTGTCAGGCCTTGAcgcggaacccctatttgt

[0235] SEQ ID NO:8

[0236] ACGACAGGGTTTGTCAGGCCTTGAcgcggaacccctatttgt

[0237] SEQ ID NO:9

[0238] Atgggttaaaaaggatcagaattcccttaccaatgcttaatcagtgaggc

[0239] SEQ ID NO:10

[0240] gggaattctgatcctttttaacccatcacatat acc tgccgttcact

[0241] SEQ ID NO:11

[0242] CTTTAAAAACCGGATCGCCTAAATGAttatttgttaactgttaattgtccttg

[0243] SEQ ID NO:12

[0244] GACTTGCTGCGCCAAGCCGGTGACTTttatttgttaactgttaattgtccttg

[0245] SEQ ID NO:13

[0246] tgacaccacgatgcctgtagc

[0247] SEQ ID NO:14

[0248] tctccggctaatgcaaagacgat

[0249] AmpR expression cassette sequence SEQ ID NO:15:

[0250] cgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaag

[0251] agtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatg

[0252] ctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccgaagaacgttttccaatg

[0253] atgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctcagaatgac

[0254] ttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgc

[0255] ggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaac

[0256] cggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactac

[0257] ttactctagcttcccggcaacaattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattg

[0258] ctgataaatctggagccggtgagcgtgggagtcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgac

[0259] ggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaa

[0260] sacB expression cassette sequence SEQ ID NO:16:

[0261]

[0262] SEQ ID NO:17

[0263] ATGAACACGATTAACATCGCTAAG

[0264] SEQ ID NO:18

[0265] TTATTACGCGAACGCGAAGTC

[0266] SEQ ID NO:19

[0267] tttacactttatgcttccggctcg

[0268] SEQ ID NO:20

[0269] GTTCTTAGCGATGTTAATCGTGTTCA

[0270] SEQ ID NO:21

[0271] gagcaccgccgccgcaaggaatggttttacactttatgcttccggc

[0272] SEQ ID NO:22

[0273] ccgggggactgttgggcgccatctccttTTATTACGCGAACGCGAAGTC

[0274] SEQ ID NO:23

[0275] tttacactttatgcttccggctcgtataatgtgtggaattgtgagcggataacaaGGCCACTACTAGAGAAAGAGGAGAAATA

[0276] CTAGATGAACACGATTAACATCGCTAAGAAC

[0277] SEQ ID NO:24

[0278] CTAACTTGAGCGAAACGGGAAGG

[0279] SEQ ID NO:25

[0280] cgtggtatgcgttacaccttgagt

[0281] SEQ ID NO:26

[0282] ctggtggcactgggtagttgttaat

[0283] SEQ ID NO:27

[0284] tcgctcaagacgtgtaatgctgcaatctTTATTACGCGAACGCGAAGTC

[0285] SEQ ID NO:28

[0286] cgtggccagtgccaagcttgcatgctttacactttatgcttccggc

[0287] SEQ ID NO:29

[0288] catctggtatcacttaaaggtattaaaaacaactttttgtctttttaGAATTCatatgaatatcctccttag

[0289] SEQ ID NO:30

[0290] tgaaatagaaaaatgaatccgttgaagcctgcttttttatactaaAAGCTTtttacactttatgcttccggc

[0291] SEQ ID NO:31

[0292] TTTTTCTCAAGCGAAAGCCGCGG

[0293] SEQ ID NO:32

[0294] TACTCCTGACAACATAAATGCGG

[0295] SEQ ID NO:33

[0296] cattcgggaaggagccgatatcat

[0297] SEQ ID NO:34

[0298] ctaatatgcatctaaaggcatggcact

[0299] SEQ ID NO:35

[0300] tacgccgtcataatcgcgtagt

[0301] SEQ ID NO:36

[0302] tgaaatcgaccttcatggcgcat

[0303] SEQ ID NO:37

[0304] ATATGAATATCCTCCTTAG

[0305] SEQ ID NO:38

[0306] TGTAGGCTGGAGCTGCTTCG

[0307] SEQ ID NO:39

[0308] ctagataaacacgctcttttgtttttccgctcagagttccaagactaatgtatatgaatatcctccttag

[0309] SEQ ID NO:40

[0310] gacaacccctattgcgatcagctcttttgcttctaccgagactttatcgtttgtaggctggagctgcttcg

[0311] SEQ ID NO:41

[0312] ggtactgagcacagcattttccggcccggcattggccgaaggtatcaatagatatgaatatcctccttag

[0313] SEQ ID NO:42

[0314] acatccgcaataaaacgtaccgggcgcgtcagcgtggacttttaccgtgtaggctggagctgcttcg

[0315] SEQ ID NO:43

[0316] atggcttcctccgaagacgttatcaaagagttcatgcgtttcaaagttcgtatggaaggttccgttaacggtcacgagttcgaaatcgaaggtgaaggtgaaggtcgtccgtacgaaggtacccagaccgctaaactgaaagttaccaaaggtggtccgctgccgttcgcttgggacatcctgtccccgcagttccagtacggttccaaagcttacgttaaacacccggctgacatcccggactacctgaaactgtccttcccggaaggtttcaaatgggaacgtgttatgaacttcgaagacggtggtgttgttaccgttacccaggactcctccctgcaagacggtgagttcatctacaaagttaaactgcgtggtaccaacttcccgtccgacggtccggttatgcagaaaaaaaccatgggttgggaagcttccaccgaacgtatgtacccggaagacggtgctctgaaaggtgaaatcaaaatgcgtctgaaactgaaagacggtggtcactacgacgctgaagttaaaaccacctacatggctaaaaaaccggttcagctgccgggtgcttacaaaaccgacatcaaactggacatcacctcccacaacgaagactacaccatcgttgaacagtacgaacgtgctgaaggtcgtcactccaccggtgcttaaSEQ ID NO:44

[0317] atgggccaccatcatcatcatcatagcagcggcgaaagcctgtttaaaggtccgcgcgattacaacccgattagtagcaccatctgccatctgaccaacgaatctgacggtcataccaccagtctgtacggtattggctttggcccgtttatcatcaccaacaaacacctgttccgccgtaacaacggtaccctgctggttcaatctctgcatggcgtcttcaaagtcaaaaacaccaccaccctgcaacagcatctgattgacggtcgcgatatgatcatcatccgcatgccgaaagatttcccgccgtttccgcagaaactgaaattccgcgaaccgcaacgcgaagaacgtatttgtctggtcaccaccaacttccagaccaaatccatgtctagcatggttagcgataccagctgtacctttccgagcagcgacggtatcttctggaaacattggatccagaccaaagacggtcaatgcggtagtccgctggttagtacccgcgacggttttatcgtcggcattcatagcgcgagcaacttcaccaacaccaacaactacttcaccagcgtcccgaaaaacttcatggagctgctgaccaaccaagaagcacagcagtgggtttctggttggcgtctgaacgcagattctgttctgtggggcggtcataaagtcttcatggtcaaaccggaagaaccgtttcagccggttaaagaagctacccagctgatgaactaa

[0318] SEQ ID NO:45

[0319] GTTTAACTTTAAGAAGGAGATATACCATGGCTTCCTCCGAAGACGTTATC

[0320] SEQ ID NO:46

[0321] GTGGTGGTGGTGGTGCTCGAGCTATTAAGCACCGGTGGAGTGACGACC

[0322] SEQ ID NO:47

[0323] gtttaactttaagaaggagatataccatgggccaccatcatcatcatcatag

[0324] SEQ ID NO:48

[0325] ggtggtggtggtggtgctcgagctattagttcatcagctgggtagcttc

Claims

1. A method for transforming Escherichia coli Nissle 1917, comprising: (a) introducing an exogenous T7 RNA polymerase expression cassette; (b) Removal of cryptic plasmids.

2. A Nissle 1917 engineered bacterium, which is transformed from Escherichia coli Nissle 1917 and is a strain having the following characteristics: (a) containing an exogenous T7 RNA polymerase expression cassette; and (b) its cryptic plasmid is removed.

3. The method according to claim 1 or the engineered bacteria according to claim 2, characterized in that: In (a), the T7 RNA polymerase expression cassette includes an operably linked (5'-3'): expression driver element, a modified ribosome binding site and a T7 RNA polymerase encoding gene; Preferably, the modified ribosome binding site comprises a ribosome binding site of 5'-aaagaggagaaa-3' sequence and a spacer sequence; the spacer sequence is 5'-ggccactactagag-3' located upstream (5' end) of the ribosome binding site, and 5'-tactag-3' located downstream (3' end) of the ribosome binding site; Preferably, the expression driving element comprises: a lactose promoter and a lactose operon; more preferably, the lactose promoter is lacUV5; preferably, the lactose promoter has a sequence of 5'-tttacactttatgcttccggctcgtataatg-3', and the lactose operon has a sequence of 5'-ttgtgagcggataacaa-3'; More preferably, the T7 RNA polymerase expression cassette has the nucleotide sequence shown at positions 1-87 in SEQ ID NO:

23.

4. The method according to claim 1 or the engineered bacteria according to claim 2, characterized in that: Also includes: (c) down-regulating the endA gene; and / or (d) Down-regulation of the ompT gene.

5. The method or engineered bacteria according to claim 1 or 4, characterized in that: (a), introducing the T7 RNA polymerase expression cassette into the genome of Escherichia coli Nissle 1917; preferably, integrating the T7 RNA polymerase expression cassette into the attB site of the genome; preferably, integrating by gene editing or homologous recombination; and / or In (b)-(d), the down-regulation or removal of the relevant gene or plasmid is performed by methods including gene knockout / silencing and gene interference; preferably, gene knockout / silencing is performed by gene editing or homologous recombination to perform the down-regulation or removal; More preferably, the gene editing is performed by CRISPR / Cas9 method; In (b), the cryptic plasmids include: pMUT1 and pMUT2.

6. A recombinant expression system of an exogenous protein, comprising: (1) The Nissle 1917 engineered bacterium according to any one of claims 2 to 5; as well as (2) An expression construct, which comprises: a T7 promoter and a foreign protein encoding gene insertion site.

7. Use of the Nissle 1917 engineered bacteria according to any one of claims 2 to 5 or the recombinant expression system for foreign proteins according to claim 6 for expressing foreign proteins.

8. A kit for expressing foreign proteins, comprising: The Nissle 1917 engineered bacteria according to any one of claims 2 to 5; or The recombinant expression system according to claim 6; Preferably, the kit further comprises an inducer, and the inducer comprises: lactose or IPTG.

9. A method for expressing a foreign protein using the recombinant expression system of foreign protein according to claim 6, comprising: (i) introducing a foreign protein encoding gene into the foreign protein encoding gene insertion site of the expression construct of (2) to obtain a recombinant expression construct; (ii) introducing the recombinant expression construct of (i) into the engineered bacteria of (1) to obtain a recombinant engineered bacteria, culturing the recombinant engineered bacteria, and expressing the exogenous protein; Preferably, in (ii), after culturing the recombinant engineered bacteria, it is induced with lactose or IPTG to express the foreign protein.

10. A modified ribosome binding site or a T7 RNA polymerase expression cassette containing the site, wherein the modified ribosome binding site comprises a ribosome binding site of a 5'-aaagaggagaaa-3' sequence and a spacer sequence; the spacer sequence is 5'-ggccactactagag-3' located upstream (5' end) of the ribosome binding site, and 5'-tactag-3' located downstream (3' end) of the ribosome binding site; The T7 RNA polymerase expression cassette includes an operably connected (5'-3'): expression drive element, a modified ribosome binding site and a T7 RNA polymerase encoding gene; the expression drive element includes: A lactose promoter and a lactose operon; preferably, the lactose promoter is lacUV5; preferably, the lactose promoter has a sequence of 5'-tttacactttatgcttccggctcgtataatg-3', and the lactose operon has a sequence of 5'-ttgtgagcggataacaa-3'; more preferably, the T7 RNA polymerase expression cassette has the nucleotide sequence shown at positions 1-87 in SEQ ID NO:23.

Citation Information

Patent Citations

  • Method for removing cryptic plasmids from escherichia coli Nissle by using suicide vectors

    CN103740747A

  • Expression assembly based on T7 expression system

    CN110218734A

  • Escherichia coli probiotic T7 expression system and application thereof

    CN116769814A

  • Genetically engineered bacterium for synthesizing fucosyllactose as well as preparation method and application of genetically engineered bacterium

    CN119101639A

  • Genetically engineered bacterium for synthesizing N-acetylglucosamine as well as preparation method and application of genetically engineered bacterium

    CN119101640A

Cited By

  • A genetically engineered bacterium for synthesizing fucosyllactose and a preparation method and application thereof

    CN119101639B

  • Genetically engineered bacterium for synthesizing N-acetylglucosamine as well as preparation method and application of genetically engineered bacterium

    CN119101640A

  • A genetically engineered bacterium for synthesizing N-acetylglucosamine, its preparation method and application

    CN119101640B

  • Tumor-targeted drug-producing engineering strain as well as construction method and application thereof

    CN119685232A

  • Genetically engineered bacterium for producing lactose-N-disaccharide as well as preparation method and application of genetically engineered bacterium

    CN120137865A